Palmetto
Cofactor Genomics Immunotherapy Response Test Nabs Medicare Coverage
The assay evaluates a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's therapy response.
Foundation Medicine, Natera Launch ctDNA Therapy Response Assay With Medicare Coverage
The tissue-informed ctDNA assay is available to US physicians and is eligible for coverage through both the MolDx and New York's CLEP programs.
Medicare Covering Epic Sciences ctDNA Breast Cancer Panel, MDxHealth's Select MDx Test
Medicare is covering the 56-gene ctDNA panel that forms one component of the DefineMBC multiomic liquid biopsy test.
Guardant Health Gets Medicare Coverage for Liquid Biopsy Treatment Response Test
The test is designed to track circulating tumor DNA levels in blood samples, enabling clinicians to evaluate patient responses to immunotherapy.
Guardant Health Receives Medicare Coverage for MRD Liquid Biopsy in Stage II and III Colon Cancer
The Guardant Reveal assay will now be covered for this group of patients as long as testing is initiated within three months after surgery.
Mar 14, 2019